Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Amazon launches GLP-1 weight loss program, promising 'fast, convenient' access
01:20pm, Tuesday, 21'st Apr 2026
Amazon One Medical launched a GLP-1 program integrating obesity care with Amazon Pharmacy. Pricing for the popular weight loss drugs will begin at as low as $25 per month with insurance.
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
09:10am, Tuesday, 21'st Apr 2026
600,000 New Wegovy® Pill Prescriptions Written in First Two Months Kelowna, British Columbia – April 21, 2026 - TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Company” or “
BODi Expands GLP-1 Support and Longevity-Driven Fitness with “10 Minute BODi” Workouts
08:00am, Tuesday, 21'st Apr 2026
EL SEGUNDO, Calif.--(BUSINESS WIRE)--BODi (NASDAQ: BODI) today announced the expansion of its 10 Minute BODi catalogue with three new digital programs, accelerating its push to make consistent fitness
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
11:20am, Friday, 17'th Apr 2026
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%. Although increasingl
Omada Health Helps Members on GLP‑1s Lose More Fat, Preserve Muscle Mass, and Improve Mental Health, New Study Finds
09:00am, Friday, 17'th Apr 2026
SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first provider of between-visit care, announced new study results demonstrating that Omada members in its GLP
Lilly's new GLP-1 pill is off to a ‘robust' start
08:28am, Friday, 17'th Apr 2026
Lilly's new GLP-1 pill had 1,390 prescriptions in its first week on the market.
RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
01:44pm, Thursday, 16'th Apr 2026
Investors are starting to focus on what will replace compounded GLP-1 driven growth for telehealth companies like Hims & Hers Health. Peptides are gaining attention as a potential new growth vector, d
Hims & Hers Health Stock Rallies on Regulatory Pivot. It's Not About GLP-1s This Time.
08:46am, Thursday, 16'th Apr 2026
Hims has signaled its interest in peptides, many of which have been banned for use in compounding pharmacies.
Hims & Hers: Bargain EBITDA Multiples As GLP-1 Drama Passes
05:58pm, Tuesday, 14'th Apr 2026
Hims & Hers has sharply declined, losing nearly 40% YTD and two-thirds from last year's peak. Despite the selloff, I see compelling value in HIMS at its current, compressed valuation. Markets have pen
Albertsons cites slower GLP-1 growth, higher gas prices for a sales miss and downbeat outlook
03:49pm, Tuesday, 14'th Apr 2026
Albertsons's stock was falling Tuesday after a sales miss and an announcement that the grocery-store chain has reached a $774 million settlement to resolve opioid-related claims.
Are Investors Undervaluing Global Partners (GLP) Right Now?
10:40am, Tuesday, 14'th Apr 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Novo Nordisk: Intense Competition Within The GLP-1 Duopoly
10:20am, Tuesday, 14'th Apr 2026
Novo Nordisk reached an all-time high of $148.15 in June 2024, when market participants were widely optimistic about the prospects of NVO's new semaglutide drug for weight management, Wegovy. After a
GLP-1 giant Novo Nordisk partners with OpenAI as pharma industry's AI race accelerates
03:33am, Tuesday, 14'th Apr 2026
The Danish drugmaker becomes the latest major pharmaceutical company to embed AI across its entire drug development pipeline, from discovery to commercial operations. Novo Nordisk (NYSE:NVO), the Dani
Global Partners Announces Cash Distribution on Series B Preferred Units
08:30am, Monday, 13'th Apr 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that the Board of Directors (the “Board”) of its general partner, Global GP LLC, has declare
Novo Nordisk's GLP-1 pill momentum faces pricing test, says leading bank
11:19am, Friday, 10'th Apr 2026
Novo Nordisk (NYSE:NVO) reports first-quarter 2026 results on 6 May, with UBS flagging that the results will provide the first meaningful look at the company's economics at new, lower price points for
